Company Overview

Update
Headquarters:
Cambridge
Funding:
$36.80M
Categories:
Biotechnology

Crescendo Biologics is engaged in the development of a proprietary drug portfolio based on their VH antibody fragment platform.

Description

Update

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.

The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Current Team (2)

Update

Funding Rounds (3) - $36.80M

Update

Investors (7)

Update

Offices/Locations (1)

Update
  • Office

    Meditrina Building 260

    Babraham Research Campus

    Cambridge, CB22 3AT

    GBR